Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04, Zacks reports.

Oramed Pharmaceuticals Trading Down 3.9 %

NASDAQ ORMP traded down $0.09 on Friday, hitting $2.21. 74,075 shares of the company were exchanged, compared to its average volume of 157,620. Oramed Pharmaceuticals has a 12 month low of $1.96 and a 12 month high of $3.14. The company has a market cap of $89.09 million, a PE ratio of 20.09 and a beta of 1.61. The stock has a fifty day moving average of $2.30 and a 200-day moving average of $2.35.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 19th.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.